Viro Chem Pharma, Inc.

Biochem Pharma Inc.

Vertex Pharmaceuticals, Inc.

Shire Biochem, Inc.

Marc Courchesne

Laval Chan Chun Kong

Christophe Moinet

Giorgio Attardo

Rabindra Rej

Monica Bubenik

Serge Lamothe

Louis Vaillancourt

Yves St-Denis

Wuyi Wang

Dieu Nguyen

Yao-Chang Xu

France Barbeau

Elaine Lebeau

Thumkunta Jagadeeswar Reddy

Oswy Z Pereira

Liliane Halab

Denis Labrecque

Charles Blais

Nathalie Chauret

Ming-Qiang Zhang

Jean-Francedillaois Lavall Ee

Tibor Breining

Jean Louis Kraus

Boulos Zacharie

Carl Poisson

Constantin G Yannopoulos

Bingcan Liu

Guy Falardeau

Shaun Abbott

Caroline Cadilhac

Bernard Belleau, Deceased

Melanie Proulx

Réal Denis

Jean-Louis Kraus

Laval Chan

Paul Nguyen-Ba

Nathalie Turcotte

Karen Meerovitch

Serge Lamonthe

Jean-Francedillaois Lavallee

The invention relates to 21-keto triterpene compounds of formula (I): wherein R, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.

C-21-keto lupane derivatives preparation and use thereof

The invention relates to 21-keto triterpene compounds of formula (I): wherein R, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment. 

Lupane derivatives useful for treating HIV

Compounds according to formula (I): wherein R, R, R, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R', and R&#x2032;are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.

Spirotropane compounds

Compounds according to formula (I): wherein A, Rand Rare as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof are useful for the modulation of CCR5 chemokine receptor activity.

Spirotropane compounds and methods for the modulation of chemokine receptor activity

Compounds according to formula (I): wherein A, R, Rand Rare defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

Compounds of formula I wherein R, R, R, Rand Rare as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

Spirohydantoin compounds and methods for the modulation of chemokine receptor activity

Compounds of formula I wherein X, Y, Z, W, Rand Ras defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

Spiro compounds and methods for the modulation of chemokine receptor activity

A novel compound which inhibits certain integrins, particularly &#x3b1;integrins. Additionally, the novel compound may be used in a method of treating tumors or cancer which comprises administering a pharmaceutically effective amount of the compound to a patient. Additionally, the novel compound may be used in a method of inhibiting angiogensis. Finally, a method of producing the novel compound is disclosed.

Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer

The present invention is directed towards novel compounds that are effective inhibitors of integrins, particularly &agr; &bgr; or &agr; integrins such as &agr; &bgr; and &agr; &bgr; . One embodiment of the present invention comprises a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. R1, R2, R3, and R4 are defined herein.

Quinolizinones as integrin inhibitors

This invention relates to a naphthoquinone derivatives, to processes and to intermediates for preparing these derivatives, to pharmaceutical composition and to the use of these derivatives as antitumor agents in mammals.

Antineoplastic heteronapthoquinones

Processes antineoplastic heteronaphthoquinones

Novel pyrano heterocyclic anthracycline derivatives are described, which are useful in the treatment of cancer and tumors, such as breast cancer, leukemia, lung cancer, colon cancer, ovarian cancer, renal cancer, and melanoma. As well, these compounds may be used ex vivo for the treatment of cancerous bone marrow before retransplanting said marrow in a patient. Pharmaceutical compositions and methods of preparing the compounds are also described.

Heterocyclic anthracycline analogs

Growing community of inventors

Laval, Canada

Marc Courchesne